Attorneys general say ‘anti-vaxxer’ accounts on Facebook, YouTube, Instagram, and Twitter reach more than 59 million followers
Decline in Exercise Linked to Higher Depression During Pandemic
Among college students, disruption to physical activity a leading risk factor for depression during the COVID-19 pandemic
Antibody Response to SARS-CoV-2 mRNA Vaccine Poor in Transplant Recipients
Anti-S1 or anti-receptor-binding domain antibody detectable in 17 percent of solid organ transplant recipients after first dose
Racial Disparities Found in Heart Care in the UK During Pandemic
Black, Asian, and minority ethnic patients less likely to receive guideline-based care, more likely to die
Vivek Murthy Confirmed as New US Surgeon General
Murthy plans to focus on COVID-19, mental health, and substance use disorders
States Receive $12.7 Billion for Alternatives to Long-Term Care Homes
Money will only be available over four calendar quarters this year and next
Predicting ‘Long COVID Syndrome’ with a Smartphone App
As devastating as this COVID-19 pandemic has been, it’s truly inspiring to see the many innovative ways in which researchers worldwide have enlisted the help of everyday citizens to beat COVID-19, said Dr. Francis S. Collins, the 16th Director of the National Institutes of Health (NIH).
Excerpts from Dr. Collins’s weekly blog continue below.
‘An intriguing example is the COVID Symptom Study’s smartphone-based app, which already has been downloaded 2.6 million times, mainly in the United States and the United Kingdom.
HPV Vaccination After 26 Years of Age Found Less Cost-Effective
The journal PLOS published a cost-effectiveness analysis that evaluated extending human papillomavirus (HPV) vaccinations to ages 30, 35, 40, or 45.
This peer-reviewed study found HPV vaccination of women and men aged 30 to 45 years provides limited health benefits at the population level, at a substantial cost.
The HPV vaccine price was the primary cost.
SARS-CoV-2 Viral-Specific Antibody Response Profiles Vary With Age
Younger children exhibit higher median IgG levels, total antibody levels, surrogate neutralizing antibody activity
Infliximab May Impede Serologic Response to SARS-CoV-2
Concomitant immunomodulator use further blunted antibody responses to SARS-CoV-2 among infliximab-treated IBD patients